Any expectations from the more powerful dulaglutide?
Authors:
Jan Škrha jr.
Authors‘ workplace:
3. interní klinika 1. LF UK a VFN, Praha
Published in:
Vnitř Lék 2022; 68(2): 124-126
Category:
In Brief
Overview
Dulaglutide is a frequently used GLP-1 analogue and one of the most potent antidiabetic drugs. Practical aspects of treatment with dulaglutide are presented in this article, together with new data from AWARD-11 study with higher concentrations of dulaglutide, especially the effects on diabetes control, body weight and side effects.
Keywords:
diabetes – dulaglutide – pharmacotherapy
Sources
1. Haluzík M. Dulaglutid. Farmakoterapie. 2018;14(1):59-64.
2. Adamíková A. Dulaglutid. Interní Medicína. 2019;21(1):62-65.
3. Mody R, Huang Q, Yu M et al. Clinical and economic outcomes among injection‑naive patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real‑world setting: the DISPEL Study. Bmj Open Diabetes Research & Care 2019;7(1).
4. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑ controlled trial. Lancet 2019;394(10193):121-130.
5. Buse JB, Wexler DJ, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43(2):487-493.
6. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‑ controlled trial. Lancet 2019;394(10193):131-138.
7. Committee ADAPP. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021;45(Supplement_1):S144-S174.
8. Frias JP, Bonora E, Nevarez Ruiz L et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin‑Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care 2021;44(3):765-773.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 2
Most read in this issue
- Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
- The position of SGLT2 inhibitors in current medical practice – update 2022
- Prediabetes
- Anticoagulation in cancer patients; new recommendations based on randomized clinical trials